| Date Filed | Type | Description |
| 02/06/2013 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/22/2013 |
SC 13G/A
| Empery Asset Management, LP reports a 2% stake in Bionovo, Inc. |
| 11/01/2012 |
8-K
| Quarterly results |
| 05/29/2012 |
8-K/A
| Form 8-K - Current report [amend] |
| 05/25/2012 |
8-K
| Other Events |
| 05/15/2012 |
10-Q
| Quarterly Report for the period ended March 31, 2012 |
| 05/08/2012 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/27/2012 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/03/2012 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2012 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials |
| 03/30/2012 |
10-K
| Annual Report for the period ended December 31, 2011 |
| 03/21/2012 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/16/2012 |
SC 13G
| Empery Asset Management, LP reports a 10% stake in Bionovo, Inc. |
| 03/13/2012 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 03/13/2012 |
8-K/A
| Form 8-K - Current report [amend] |
| 03/12/2012 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Form of Warrant",
"Securities Purchase Agreement",
"Bionovo Enters Into Agreement for Offering of Common Stock and Warrants EMERYVILLE, Calif. – March 12, 2012 — Bionovo, Inc. On March 12, 2012, Bionovo, Inc., entered into a securities purchase agreement with investors to purchase an aggregate of 14,231,696 shares of our common stock, par value $0.0001 per share . The aggregate purchase price for the Common Shares is approximately $426,951. Additionally, each Investor will receive a warrant exercisable into shares of our common stock. The Warrants shall be exercisable into an aggregate of 11,485,844 shares of our common stock at an exercise price of $0.03 per share. The Warrants expire on March 30, 2012. If the Warrants are exercised in full for cash, the Company will receive approximately an additional $344,575 in proceeds. The Common Shar..." |
|
| 03/01/2012 |
8-K
| Termination of a Material Definitive Agreement |
| 02/17/2012 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 02/09/2012 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 02/08/2012 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933 |
| 01/27/2012 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 01/10/2012 |
SC 13G
| Crede CG II, Ltd. reports a 9.9% stake in Bionovo, Inc. |
| 01/06/2012 |
8-K
| Form 8-K - Current report |
| 01/04/2012 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 11/16/2011 |
PRN
| Bionovo Announces "First Patient, First Dose" in Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes |
| 11/10/2011 |
8-K
| Form 8-K - Current report |
| 11/10/2011 |
10-Q
| Quarterly Report for the period ended September 30, 2011 |
| 11/10/2011 |
PRN
| Bionovo Announces Third Quarter 2011 Highlights and Financial Results |
| 09/19/2011 |
8-K
| Form 8-K - Current report |
| 08/30/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/30/2011 |
PRN
| Bionovo Announces Positive Results of the Tolerability Trial of Menerba (MF101) for Menopausal Hot Flashes |
| 08/08/2011 |
8-K/A
| Form 8-K - Current report [amend] |
| 08/03/2011 |
10-Q
| Quarterly Report for the period ended June 30, 2011 |
| 05/13/2011 |
8-K
| Form 8-K - Current report |
|